Dupont De Nemours, Inc. · NYSE:DD
Dupont De Nemours — Merger or Acquisition (May 2023)
18 slides from Dupont De Nemours's merger presentation, May 2, 2023
Slide 1: DuPont to Acquire Spectrum Plastics Group
DuPont to Acquire Spectrum Plastics Group Expanding Material Science Offering in Healthcare DuPont Announcement: May 2, 2023
Slide 2: Forward-looking Statements
Forward-looking Statements This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking
Slide 3: Executive summary
Executive summary Significantly enhances DuPont’s offerings of high-value, material science-driven solutions for healthcare Spectrum Plastics Group ("Spectrum") is a recognized leader in the design and manufacturing of complex medical parts and devices ~$500 million revenue expected in 2023 Combines
Slide 4: Transaction summary
Transaction summary Financial impact • $1.75 billion purchase price • $1.72 billion net purchase price¹ • 15.6x 2023e EBITDA; 13.2x with cost synergies o ~$20 million pre-tax run-rate cost synergies • Funded with existing cash on balance sheet • Immediately accretive to adjusted EPS • High single-di
Slide 5: Our healthcare background
Our healthcare background <OUPONT>
Slide 6: Focused on five growth pillars
Focused on five growth pillars Industrial Technologies leverages growth from material science-based innovation Electronics Water Protection Industrial Next Generation Technologies Automotive 33% 12% 22% 20% 13% of net sales1 of net sales1 of net sales1 of net sales1 of net sales1 • Consumer electron
Slide 7: Long-term track record serving healthcare markets
Long-term track record serving healthcare markets ~$800 million annual revenue from two leading businesses with high growth and strong margins Liveo™ Healthcare Solutions Tyvek® for Healthcare Packaging A leader in silicone healthcare solutions with best-in-class formulation Trusted partner for medi
Slide 8: DuPont Liveo: Leader in silicone solutions for healthcare applications
DuPont Liveo™: Leader in silicone solutions for healthcare applications Differentiated medical silicones capability Biopharma LDD growth 40% • Broad healthcare application expertise • Best-in-class silicone formulation capabilities, delivering on stringent customer specifications Pharma • Broad port
Slide 9: Spectrum overview
Spectrum overview <OUPONT>
Slide 10: Spectrum: A leader in specialty medical devices
Spectrum: A leader in specialty medical devices ~$500M >12% CAGR • A leader in design and manufacturing of 2023E revenue¹ 2019-2023E¹ complex, hard-to-manufacture medical devices • Supply custom solutions to 22 of top 26 medical device OEMs 190+ 2,200 Engineers Employees • Long-term customer relatio
Slide 11: Spectrum's broad product portfolio
Spectrum's broad product portfolio Interventional and Specialty Advanced fluid Specialty and medical surgical technologies molding management flexibles 11
Slide 12: Spectrum's differentiation and technology capabilities
Spectrum’s differentiation and technology capabilities Deep process design and manufacturing execution capabilities Competitive Differentiation Technology capabilities Speed & innovation Additive • Best-in-class lead times utilizing proprietary Precision polymer manufacturing Balloon design and manu
Slide 13: The combined healthcare portfolio
The combined healthcare portfolio 13
Slide 14: Combination significantly expands TAM
Combination significantly expands TAM $11 billion total addressable market with high single-digit growth Medical Devices BioPharma $8.5B 6-8% $2.5B 10-12% total addressable annualized total addressable annualized market growth rate market growth rate Macro trends Macro trends • Miniaturization for c
Slide 15: Combination creates a full-service solutions provider
Combination creates a full-service solutions provider Combined portfolio Medical devices • Material science • Advanced manufacturing • Direct OEM relationships Biopharma & Pharma • Material science • Advanced manufacturing • Direct OEM relationships $800M $500M $1.3B revenue* revenue* revenue* HSD g
Slide 16: Expanded opportunities in medical devices and biopharma
Expanded opportunities in medical devices and biopharma Linking customer co-development and broader product and service offering Example: New medical and pharma solutions Example: Expanding biopharma fluid transfer solutions with upstream offerings Upstream Downstream Remote Patient Monitor Drug Del
Slide 17: A powerful combination
A powerful combination ~10% of consolidated DuPont revenue to be derived from healthcare markets Adds high-growth, low cyclicality, high margin healthcare exposure for DuPont 17
Slide 18: © 2023 DuPont. All rights reserved. DuPont™, the DuPont Oval Logo, and all trademarks
© 2023 DuPont. All rights reserved. DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. Nothing contained herein shall be construed as a representation that any recommendations, use or r